Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Hikal Limited is an Indian pharmaceutical and agrochemical manufacturer operating contract development and manufacturing (CDMO) facilities across multiple sites in India. The company produces active pharmaceutical ingredients (APIs), advanced intermediates, and crop protection chemicals for global customers, with significant exposure to regulated markets including the US and Europe. The stock trades on operational efficiency, capacity utilization, and customer contract wins in a competitive CDMO landscape.
Hikal operates as a contract manufacturer with multi-year supply agreements for pharmaceutical APIs and agrochemical intermediates. Revenue is generated through cost-plus or fixed-price contracts with global pharmaceutical and agrochemical companies. Pricing power derives from regulatory approvals (US FDA, EU GMP), technical expertise in complex chemistry, and established manufacturing scale. The company benefits from India's cost advantage in chemical synthesis while maintaining quality standards required for regulated markets. Margins depend on capacity utilization (typically 70-85%), product mix complexity, and raw material pass-through arrangements.
New customer contract wins and renewals - particularly multi-year API supply agreements with large pharmaceutical companies
Capacity utilization rates across manufacturing facilities - optimal range 75-85% drives margin expansion
Regulatory audit outcomes - US FDA inspection results, warning letters, or facility clearances significantly impact valuation
Raw material cost inflation - particularly key chemical intermediates sourced from China and domestic suppliers
Product mix shift - movement toward higher-margin complex APIs versus commodity intermediates
Regulatory compliance risk - US FDA or EU regulatory actions including warning letters, import alerts, or facility restrictions can immediately halt revenue from affected sites and damage customer relationships
China API competition - Chinese manufacturers with lower cost structures and increasing quality standards pose ongoing competitive threat, particularly in commodity APIs and intermediates
Environmental regulations - increasing scrutiny on chemical manufacturing effluents and emissions in India may require significant compliance capex and operational restrictions
Customer concentration - loss of major pharmaceutical or agrochemical customers (typically top 5 customers represent 40-50% of revenue) would significantly impact utilization and margins
Pricing pressure from generic drug deflation - as branded drugs lose patent protection, API pricing faces compression from generic competition and buyer consolidation
Technology disruption - continuous manufacturing and flow chemistry adoption by competitors could render traditional batch manufacturing less competitive
Working capital intensity - CDMO business model requires 90-120 days of working capital, creating cash flow volatility with revenue growth or customer payment delays
Capex requirements - maintaining regulatory compliance and competitive manufacturing capabilities requires ongoing capital investment of 7-10% of revenue, limiting free cash flow generation
Currency exposure - revenue earned in USD/EUR while significant costs in INR creates translation risk, though natural hedge exists through imported raw materials
moderate - Pharmaceutical API demand is relatively stable driven by chronic disease treatment and generic drug penetration, providing defensive characteristics. However, agrochemical segment (35-40% of revenue) exhibits cyclicality tied to crop prices, farmer economics, and agricultural production cycles. Overall business shows moderate GDP sensitivity with pharmaceutical segment providing stability offset by agrochemical volatility.
Rising interest rates moderately impact Hikal through higher financing costs on working capital (given 90-120 day cash conversion cycle) and capex funding. With debt/equity of 0.57, interest expense represents approximately 2-3% of revenue. Rate increases also compress valuation multiples for mid-cap pharmaceutical manufacturers as investors demand higher equity risk premiums. However, operational cash flow generation (15% of revenue) provides partial offset.
Moderate credit exposure through customer payment terms (typically 60-90 days) and working capital financing needs. Pharmaceutical customers generally have strong credit profiles, but agrochemical distributors in emerging markets carry higher default risk. Tightening credit conditions can extend customer payment cycles and increase working capital requirements, pressuring cash flow.
value - The stock trades at 1.5x P/S and 13.9x EV/EBITDA with 5.7% FCF yield, attracting value investors seeking exposure to India's pharmaceutical manufacturing sector at reasonable valuations. The 41% decline over 12 months despite 30% earnings growth suggests deep value opportunity or unresolved operational concerns. Investors focus on operational turnaround potential, regulatory clearances, and margin recovery as capacity utilization improves.
high - Stock exhibits high volatility with 41% decline over 12 months and 20% decline over 6 months, reflecting regulatory uncertainty, customer concentration risk, and mid-cap liquidity constraints. Beta likely exceeds 1.2-1.4 relative to Indian equity indices. Volatility spikes occur around FDA inspection announcements, quarterly earnings surprises, and major customer contract news.